Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864026 | 1.00 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL863344 | 0.86 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL863343 | 0.86 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL864008 | 0.86 | KDM4E (0.42) | KDM4ESMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL864007 | 0.86 | KDM4E (0.42) | KDM4ESMN1; SMN2ALDH1A1PIK3CDTSHR | |
| SCHEMBL12769215 | 0.74 | ALDH1A1 (0.36) | KDM4ESMN1; SMN2ALDH1A1KCNN3CYP1A2 | |
| SCHEMBL2112939 | 0.73 | SOS1 (0.33) | PIK3CDKCNN3 | |
| SCHEMBL2112940 | 0.73 | SOS1 (0.33) | PIK3CDKCNN3 | |
| SCHEMBL863593 | 0.73 | KCNN3 (0.38) | KDM4EPIK3CDKCNN3 | |
| SCHEMBL863594 | 0.73 | KCNN3 (0.38) | KDM4EPIK3CDKCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | KDM4E 2074/4885SMN1; SMN2 2993/4885ALDH1A1 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.